Market Overview

Teva Receives Approval For SYNRIBOTM

Share:
Related TEVA
Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
4 IBD 50 Drugmakers Getting Lift From New Treatments (Investor's Business Daily)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved SYNRIBO (omacetaxine mepesuccinate) for Injection to treat adult patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). The indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO. It will be available for prescribing shortly.

Previously, CP and AP CML patients who failed on two or more TKIs have had limited treatment options. “While the CML treatment landscape has seen advancements with available TKI treatments, there are still cases where patients may not be able to continue using TKIs due to issues such as resistance, intolerance, suboptimal response, and disease progression,” said Jorge E. Cortes, M.D., deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. “With SYNRIBO, physicians will now have access to another option, offering potential hope to patients who experience treatment failure.”

Posted-In: News FDA

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters